Published in Cancer Res on April 15, 2010
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res (2012) 1.83
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol (2012) 1.74
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Combined hepatocellular cholangiocarcinoma: a case report and review of literature. Dig Dis Sci (2013) 1.44
Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet (2011) 1.20
Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int (2011) 1.14
Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods (2013) 1.08
Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci (2011) 1.08
Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog (2011) 1.05
Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol (2011) 1.00
Perspectives of integrative cancer genomics in next generation sequencing era. Genomics Inform (2012) 0.94
Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol (2014) 0.93
New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J Gastroenterol (2013) 0.92
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling regulates mitochondrial biogenesis and respiration via estrogen-related receptor α (ERRα). J Biol Chem (2013) 0.92
Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer (2015) 0.92
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. PLoS One (2014) 0.86
Hepatic progenitor cells: their role and functional significance in the new classification of primary liver cancers. Liver Cancer (2013) 0.86
Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84
SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis. J Pathol Transl Med (2015) 0.82
Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring. PLoS One (2013) 0.81
Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma. Med Mol Morphol (2012) 0.80
Utilizing signature-score to identify oncogenic pathways of cholangiocarcinoma. Transl Cancer Res (2013) 0.77
Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr (2017) 0.76
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell (2017) 0.75
Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. World J Hepatol (2017) 0.75
Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. Gastrointest Cancer (2015) 0.75
Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr (2017) 0.75
Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. Oncotarget (2016) 0.75
Joint analysis of multiple high-dimensional data types using sparse matrix approximations of rank-1 with applications to ovarian and liver cancer. BioData Min (2016) 0.75
Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat Oncol (2015) 0.75
Prohibitin 1 Suppresses Liver Cancers Tumorigenesis in Mice and Human Hepatocellular and Cholangiocarcinoma cells. Hepatology (2016) 0.75
Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther (2017) 0.75
Mutations acquired by hepatocellular carcinoma recurrence give rise to an aggressive phenotype. Oncotarget (2016) 0.75
Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol (2017) 0.75
Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. Nat Commun (2017) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 34.93
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Genomic targets of the human c-Myc protein. Genes Dev (2003) 9.67
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (2003) 7.30
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Cholangiocarcinoma. Lancet (2005) 6.01
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene (2007) 4.27
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells (2007) 3.62
Combined liver cell and bile duct carcinoma. Am J Pathol (1949) 3.05
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40
Liver stem cells and hepatocellular carcinoma. Hepatology (2009) 2.27
The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology (2006) 2.18
Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell (2009) 2.14
Liver cancer stem cells. J Clin Oncol (2008) 1.82
Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res (2007) 1.73
Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology (2008) 1.46
Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res (2008) 1.41
Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol (1996) 1.35
Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology (1999) 1.30
Gene expression pattern in hepatic stem/progenitor cells during rat fetal development using complementary DNA microarrays. Hepatology (2004) 1.06
Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol (2004) 1.04
C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology (2008) 1.03
Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol (2008) 1.00
CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer (2006) 0.94
Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63-positive basal/stem-cell phenotype. Pathol Res Pract (2005) 0.90
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg (2012) 3.15
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81
Birth of parthenogenetic mice that can develop to adulthood. Nature (2004) 2.75
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology (2012) 2.44
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol (2003) 2.36
Esophageal varices in patients with cirrhosis: multidetector CT esophagography--comparison with endoscopy. Radiology (2007) 2.21
GTF2IRD1 in craniofacial development of humans and mice. Science (2005) 2.15
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med (2007) 2.09
Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol (2004) 2.06
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol (2008) 2.03
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Stage migration effect on survival in gastric cancer surgery with extended lymphadenectomy: the reappraisal of positive lymph node ratio as a proper N-staging. Ann Surg (2012) 1.96
Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol (2005) 1.95
Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol (2012) 1.94
DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene (2004) 1.90
Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut (2013) 1.89
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res (2011) 1.83
[Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis]. Korean J Hepatol (2008) 1.83
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther (2011) 1.81
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80
Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology (2014) 1.79
Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft. Liver Transpl (2009) 1.79
Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol (2009) 1.79
Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology (2010) 1.78
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (2011) 1.78
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene (2003) 1.76
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas (2006) 1.72
Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology (2011) 1.71
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 1.71
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res (2005) 1.70
Three-quarters of right liver donors experienced postoperative complications. Liver Transpl (2007) 1.70
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene (2004) 1.65
Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments. Clin Chem (2005) 1.64
Synchronous and metachronous cancers in patients with gastric cancer. J Surg Oncol (2008) 1.62
Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci (2009) 1.61
An artificial vascular graft is a useful interpositional material for drainage of the right anterior section in living donor liver transplantation. Liver Transpl (2007) 1.61
Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol (2009) 1.60
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell (2002) 1.57
Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology (2006) 1.56
Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology (2003) 1.53
Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Ann Surg (2016) 1.52
Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene (2003) 1.52
Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol (2008) 1.52
Spontaneous cryptococcal peritonitis in patients with liver cirrhosis. Am J Med (2006) 1.51
Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology (2002) 1.51
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol (2003) 1.48
Hepatic resection compared to percutaneous ethanol injection for small hepatocellular carcinoma using propensity score matching. J Gastroenterol Hepatol (2007) 1.47